Arsenal Biosciences, Inc. clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-21
What changed in the last 30 days
3 trials changed in the last 30 days: 2 stopped, 1 with a notable change, 0 with minor changes only.
- Stopped: AB-3028, a Programmable Circuit T Cell Therapy · Castration Resistant Prostate Cancer (CRPC) Trial terminated
- Notable: AB-2100, an Integrated Circuit T Cell Therapy · Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) Primary completion pushed from Mar 31, 2026 to Dec 31, 2026
- Stopped: AB-1015, an Integrated Circuit T (ICT) Cell Therapy · Platinum Resistant Epithelial Ovarian Cancer Trial terminated
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 1/2 | 1 |
Disease areas by active trials
Kidney Cancer (1)
Get alerts when Arsenal Biosciences, Inc.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.